Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Deal value includes upfront payment of US$100 million with F2G eligible for additional regulatory and commercial milestones of up to US$380 million, as well as double-digit royalties on net

Related Keywords

Boston ,Massachusetts ,United States ,Austria ,Denmark ,Copenhagen ,Køavn ,United Kingdom ,London ,City Of ,San Francisco ,California ,Naveed Siddiqi ,Eric Snyder ,Francesco Maria Lavino ,Novo Nordisk ,Shionogi Co Ltd ,Partner At Novo Holdings ,Senior Partner At Novo Holdings ,Novo Group ,Validation Of Novo Holding ,Prnewswire Novo Holdings ,Cg Ltd ,Us Food Drug Administration ,Novo Nordisk Foundation ,Novo Holdings ,Novo Holding ,Senior Partner ,Board Member ,Breakthrough Therapy Designation ,Drug Administration ,Board Director ,Inovo Venture ,Maria Lavino ,Chief Executive Officer ,Inovo Ventures ,Novo ,Oldings ,Portfolio ,Company ,Centers ,Strategic ,Collaboration ,Shionogi ,Commercialise ,Antifungal ,Agent ,Lorofim ,Europe ,Sia ,